Conference: 5th International Conference on Quality and Evidence Based in Prophetic Medicine
Keywords: Prophetic Medicine, Quality
Bronchial asthma is a growing major public health problem worldwide. Anti-inflammatory agents have been suggested to alleviate asthma. Grape seed extract (GSE) has been reported to have a powerful antioxidant and anti-inflammatory properties. The present study aims to determine whether GSE has a therapeutic effect on allergic airway inflammation in mice. Airway inflammation was induced via intraperitoneal (i.p) injected with 10 ug ovalbumin plus 2 mg aluminum hydroxide in 200 uL phosphate buffered saline (PBS). Male mice (n=50) were divided to five equal groups. The first group; negative control received i.p. injection of PBS, the second group; positive control; asthma-model (OVA), the third group; asthma mice treated orally with montelukast (30 mg/kg), the fourth group; asthma treated orally with GSE at a dose level of (150 mg/kg) and the fifth group; asthma mice treated with both GSE+ montelukast. Montelukast and GSE were given on day 27 and from day 28 to 30 1hr before each challenge. The inflammatory cytokines interleukin-5 &13 (IL-5& IL-13) were estimated in bronchoalveolar lavage fluid (BALF) and immunoglobulin E(IGE) was determined in plasma. Lung levels of pro-oxidants; malondialdehyde (MDA), nitric oxide (NO) and superoxide dismutase (SOD) were determined. Lung samples from mice in different groups examined microscopically. There was a significant increase (p<0.001) in BALF levels of IL-5 and IL-13, plasma IGE, as well asa significant increase (p<0.001) in the lung levels of NO and MDA with a significant decrease (p<0.001) in SOD levels when compared with control group. Histopathological studies of lung confirmed these results, bronchiolar and perivascular infiltrates, as well as perivascular oedema were shown in the lung tissues of OVA mice. While mice administrated GSE either alone or with montelukast showed a significant improvement in all the tested parameters. The treatment afforded by co-administration of GSE and montelukast was found to be better than that of montelukast alone. Results of the present study suggest that montelukast should be used along with GSE for better immune-regulatory effect, as well as, to reduce drugs adverse effects. Therefore, GSE seems to be a potential new drug to modulate inflammatory response in asthma.